Psilocybin Is Closer to FDA Approval Than Most People in Treatment Know. Here's the Timeline.

The FDA this month granted national priority review vouchers to three psychedelic companies — Compass Pathways (COMP360 psilocybin for treatment-resistant depression), Usona Institute (psilocybin for major depressive disorder), and Transcend Therapeutics (methylone for PTSD). Priority vouchers compress FDA review timelines from the standard 10–12 months to 1–2 months — not approval, but a significantly faster path to a decision.

Psilocybin is closer to FDA approval than most people in addiction treatment know, and that gap is about to start mattering clinically.

Compass Pathways has now run two consecutive positive Phase 3 trials for treatment-resistant depression — the first in June 2025, the second in February 2026. The company is targeting a rolling NDA submission in Q4 2026. With a priority voucher in hand, FDA review could conclude in 2027 rather than 2028. That’s not a distant hypothetical. That’s the drug approval calendar for the next 12 to 24 months.

A few things this news doesn’t mean: FDA approval of psilocybin for treatment-resistant depression is not FDA approval for addiction treatment. The Compass trials enrolled people with MDD, not people with alcohol or opioid use disorder, though there is mounting evidence of crossover effects and trial designs targeting addiction are in earlier stages. State law and prescriber scope-of-practice requirements will still gate what a clinician in Arizona can actually do the week after an FDA approval — approval changes the federal classification, not the entire delivery infrastructure overnight.

And the cautionary note that the industry hasn’t forgotten: MDMA-assisted therapy for PTSD was rejected by the FDA’s advisory committee in August 2024 by a 9-2 vote. Lykos Therapeutics’ failure stemmed in part from study design and functional unblinding concerns — problems other developers are now designing around explicitly. The post-Lykos trial redesign is one reason Compass’s Phase 3 wins carry more weight: they’re not repeating the methodological errors that sank MDMA’s first shot at approval.

For treatment providers: if psilocybin receives FDA approval for TRD in 2027, the first patients appropriate for referral will be people with depression severe enough to have failed at least two adequate antidepressant trials — many of whom also have co-occurring SUD. Begin thinking now about what a referral pathway looks like from your program to a certified psilocybin administration site, because the infrastructure is going to be built faster than the clinical education that supports it.